Antibacterial activity of naltrexone and its combination with ciprofloxacin against Gram negative and Gram positive bacteria

Year 2024, Volume: 7 Issue: 2, 55 - 59, 28.11.2024

Ertuğrul Özbil , Sultan Öğmen , Mehmet İlktaç

https://doi.org/10.54994/emujpharmsci.1573570

Abstract

Naltrexone, an opioid receptor antagonist, is commonly used in the treatment of alcoholism. Studies about the antibacterial activity of naltrexone are limited. In our study, we aimed to evaluate the antibacterial and synergistic activities of naltrexone against Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603. The results showed promising antibacterial activity against all tested pathogenic bacteria. Additionally, checkerboard assays revealed additive activity against S. aureus when combined with ciprofloxacin. Collectively, the data from our study suggest that naltrexone can further be used as a potential antibacterial source alone or in combination with other antibiotics in the treatment of bacterial infections.

Keywords

Antibacterial, Checkerboard, Ciprofloxacin, Naltrexone

References

• Bellio P, Fagnani L, Nazzicone L, Celenza G (2021). New and simplified method for drug combination studies by checkerboard assay. MethodsX 8: 101543.
• Bolton MJ, Chapman BP, Van Marwijk H (2020). Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep 13: e232502.
• Cant R, Dalgleish AG, Allen RL (2017). Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular Toll-Like Receptors. Front Immunol 8(809).
• El Shehaby DM, Mohammed MK, Ebrahem NE, El‑Azim MMA, Sayed IG, et al. (2022). The emerging therapeutic role of some pharmacological antidotes in management of COVID-19. The Egyptian Journal of Bronchology 16: 5.
• Gekker G, Lokensgard JR, Peterson PK (2001). Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. Drug Alcohol Depend 64(3): 257-263.
• Greeneltch KM, Haudenschild CC, Keegan AD, Shi Y (2004). The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-a production. Brain, Behavior, and Immunity 18: 476-484.
• Lobmaier PP, Kunoe N, Gossop M, Waal H (2011). Naltrexone depot formulations for opioid and alcohol dependence: A systematic review. CNS Neurosci Ther 17: 629-636.
• Marangaloo RG, Pinar O, Mehmedov T, Or ME (2024). Current pharmacotherapeutic properties of low-dose naltrexone therapy in humans and possible therapeutic and prophylactic indications in cats and dogs. Ger J Vet Res 4(1): 39-45.
• Sudakin D (2016). Naltrexone: Not Just for opioids anymore. J Med Toxicol 12: 71-75.
• Wikler MA (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard, vol. 26, p M7-A7. CLSI, Wayne, Pennsylvania.
• Younger J, Parkitny L, McLain D (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 33(4): 451-459.